Analysis of drug panels in urine samples can be challenging, and the trend towards larger panels including multiple drug classes compounds the issues faced during method development.
This white paper examines a number of aspects of sample preparation, and their impact on the success of subsequent LC-MS/MS analysis of broad urine panels. Originally published in 2017, the white paper has now been updated to include details of additional hydrolysis enzymes and optimum hydrolysis conditions.
In addition, since the original publication of the white paper, a further 50 analytes have been added to the urine panel, and the update includes details on how they perform using the methodologies described. An appendix outlining Biotage® Extrahera™ settings for processing the sample preparation products is also included.
DryVap® Inline Concentration System
Webinar Recording: Opioids - Choosing the Best Solution for your Laboratory
Notice of Discontinuation of Biotage ZIP® and Biotage ZIP® Sphere
An Environmental Chemist Speaks Out
Drugs of Abuse Urine Testing White Paper Updated to Include a Further 50 Analytes